For decades, scientists have looked for correlates for schizophrenia in the brain. The ultimate hope is that clinicians can use the biological information of a given individual to prevent illness onset and progression, develop new treatments, or use personalise already available treatments.
In this video, Dr. Jose M. Rubio share his insights on why we need biomarkers for Schizophrenia, why we don’t already have biomarkers for Schizophrenia, what’s necessary to bring biomarkers to the clinic and how today’s neuroimaging tools have significantly progressed the development of clinically applicable biomarkers.
Related content
Continuous maintenance therapy is associated with a lower risk of relapse than intermittent treatment, supporting ongoing treatment strategies in schizophrenia and related psychotic disorders.
Treatment response tends to be higher during a first episode than during subsequent episodes, emphasizing the importance of early intervention and effective management.
Negative symptoms are a core feature of schizophrenia and can have a profound impact on functioning, social relationships, and quality of life.